GlassScriptPhysician profile
Michael L Saruk
NPI 1235197997
$4,274.87
in general payments reported to CMS, 2019-2025
28 companies · $662 in 2025
The $662 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,016 · 2020: $247 · 2022: $348 · 2023: $931 · 2024: $1,070 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,486 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,485.68 |
| Education | $177.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,371.20 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $709.57 | 2019-2025 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $240.41 | 2020-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $213.12 | 2019-2025 | |
| Genzyme Corporation | $184.24 | 2019-2025 | |
| Lilly USA, LLC | $181.24 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $180.24 | 2019-2020 | |
| Galderma Laboratories, L.P. | $165.41 | 2019-2025 | Aklief |
| Genentech USA, INC. | $139.20 | 2019-2024 | Erivedge |
| Incyte Corporation | $110.17 | 2023-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $89.82 | 2019-2025 | |
| Almirall LLC | $72.10 | 2024-2025 | Klisyri |
| Amgen INC. | $66.09 | 2019-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $63.91 | 2019-2024 | Siliq |
| Strata Skin Sciences, INC. | $62.43 | 2024-2025 | Xtrac |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $56.58 | 2023-2024 | Sotyktu |
| Dermira, INC. | $54.40 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.04 | 2024 | Trulance |
| Prugen, INC. Pharmaceuticals | $41.97 | 2019 | |
| Biofrontera INC. | $41.29 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Journey Medical Corporation | $31.99 | 2022-2024 | |
| Dermavant Sciences, INC. | $31.34 | 2023-2024 | Vtama |
| Organon LLC | $22.65 | 2025 | Vtama |
| Ucb, INC. | $22.49 | 2024 | Bimzelx |
| Verrica Pharmaceuticals INC. | $21.00 | 2024 | Ycanth |
| Hologic Sales and Service, LLC | $17.37 | 2023 | Fluent Fluid Management System |
| Lnhc, INC | $17.25 | 2025 | Zelsuvmi |
| Pfizer INC. | $13.35 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Saruk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.